Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-10 pm EDT			5-day change	1st Jan Change
51.29 ^USD	-0.93%		+7.80%	+56.56%

Mar. 23	Damora Therapeutics, Inc. Announces Executive and Board Changes	CI
Mar. 16	Spyre Therapeutics, Inc. Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Third Quarter 2026	CI

Transcript : Spyre Therapeutics, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 03

Published on 03/11/2026 at 12:20 am EDT

S&P Capital IQ

Presenter Speech
Tyler Van Buren (Analysts)

Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference. Saving the best for

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Spyre Therapeutics, Inc.

Mar. 23	Damora Therapeutics, Inc. Announces Executive and Board Changes	CI
Mar. 16	Spyre Therapeutics, Inc. Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Third Quarter 2026	CI
Mar. 16	Spyre Therapeutics Says Recruitment for Skyway Rheumatoid Arthritis Sub-Study Completed	MT
Mar. 16	Spyre announces acceleration of expected topline readout of Skyway rheumatoid arthritis sub-study to Q3 2026	RE
Mar. 11	Spyre Therapeutics, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08:40 AM
Mar. 11	Spyre Therapeutics, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 03:10 PM
Feb. 23	Deutsche Bank Adjusts Spyre Therapeutics PT to $55 From $45, Maintains Buy Rating	MT
Feb. 20	Top Midday Gainers	MT
Feb. 19	Spyre Therapeutics files for mixed shelf of up to $500 million	RE
Feb. 19	Spyre Therapeutics Q4 Loss Narrows, Cash Runway Expected Into Q2 2028	MT
Feb. 19	Earnings Flash (SYRE) Spyre Therapeutics Posts Q4 Loss $-0.70, vs. FactSet Est of Loss of $-0.71	MT
Feb. 19	Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Jan. 22	MBX Biosciences, Inc. Announces Board and Committee Changes	CI
Jan. 12	Spyre Therapeutics Inc - Skyline trial in UC completes SPY001 enrollment ahead of schedule	RE
Jan. 12	Spyre Therapeutics, Inc. Appoints Kate Tansey Chevlen as Chief Commercial Officer	CI